Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)
14.70
-0.16 (-1.08%)
Sep 23, 2026, 3:00 PM CST
SHA:603896 Revenue
Zhejiang Shouxiangu Pharmaceutical had revenue of 115.01M CNY in the quarter ending June 30, 2026, a decrease of -7.08%. This brings the company's revenue in the last twelve months to 616.54M, down -4.54% year-over-year. In the year 2025, Zhejiang Shouxiangu Pharmaceutical had annual revenue of 640.18M, down -9.21%.
Revenue (ttm)
616.54M
Revenue Growth
-4.54%
P/S Ratio
4.78
Revenue / Employee
550.97K
Employees
1,119
Market Cap
2.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 640.18M | -64.93M | -9.21% |
| Dec 31, 2024 | 705.11M | -79.24M | -10.10% |
| Dec 31, 2023 | 784.35M | -44.72M | -5.39% |
| Dec 31, 2022 | 829.07M | 61.93M | 8.07% |
| Dec 31, 2021 | 767.14M | 131.09M | 20.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Qingdao Vland Biotech INC. | 1.42B |
| Beijing Kawin Technology Share-Holding | 1.23B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Hubei Goto Biopharm Group | 650.05M |
| Guanhao Biotech | 361.40M |
| Yantai Zhenghai Biotechnology | 336.07M |